Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)
NCT ID: NCT06830486
Last Updated: 2025-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2022-02-14
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Tailored Exercise Prescriptions in Breast Cancer Patients
NCT02802826
Effect of a Program of Physical Activity and Nutritional Therapeutic Education in Breast Cancer Patients
NCT04109326
Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors
NCT02763228
Appetite and Exercise in Breast Cancer Survivors
NCT04300478
Optimization of Remotely Delivered Physical Activity Intervention for Breast Cancer Survivors
NCT03131440
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SERM
These patients are being treated with a SERM for at least one year prior to enrolling in the study.
No intervention
No intervention is performed. Participants who have been treated with either a SERM or aromatase inhibitor are recruited and analyzed in separate groups, but the study design for all participants is identical.
Aromatase Inhibitor
These patients are being treated with an aromatase inhibitor for at least one year prior to enrolling in the study.
No intervention
No intervention is performed. Participants who have been treated with either a SERM or aromatase inhibitor are recruited and analyzed in separate groups, but the study design for all participants is identical.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention is performed. Participants who have been treated with either a SERM or aromatase inhibitor are recruited and analyzed in separate groups, but the study design for all participants is identical.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with breast cancer
* age 18-80 years
* Completed surgery, chemo- and/or radiation therapy
* Prescribed aromatase inhibitor or SERM for at least one year from the time of screening
Exclusion Criteria
* Type 1 diabetes
* Type 2 diabetes
* Prescribed anti-hyperglycemic medication, insulin, or sulfonylurea.
* Pregnant, breastfeeding or planning to become pregnant in next 2 months
* Have absolute contraindications to exercise testing which are:
1. Unstable angina
2. Recent myocardial infarction, cardiac surgery, or vascular surgery (\<3 months)
3. Uncontrolled high blood pressure
4. Heart failure
5. Peripheral artery disease (based on report of symptomatic claudication)
6. Hepatic or renal disease
7. Severe arthritis or mobility impairment that would interfere with exercise testing
* Suspected cognitive impairment that would prevent understanding or comprehension of study procedures.
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Colorado State University
OTHER
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rebecca Scalzo, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-3245.cc
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.